As such, we are involved in the Marseille immunology biotope
I am the Director of Protisvalor, the research transfer subsidiary of Aix-Marseille University. Protisvalor was founded in 2002 to provide laboratories and researchers with the necessary assistance to valorize their expertise and the results of their research. Since then, we have actively supported the University’s teams in their innovation activities and collaborations with industry and ensure the administrative and financial management of strategic R&D platforms, such as the MI-mAbs pre-industrial demonstrator.
As such, we are involved in the Marseille immunology biotope, so it is natural that today we fully support this initiative.#ecosystem
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
AMU, IPC, CRCM
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!